Hello, and welcome to the Axogen, Inc. 2023 Fourth Quarter and Full Year Financial Results Conference Call and Webcast. If anyone should require operator assistance, please press star zero on your telephone keypad. A question-and-answer session will follow the formal presentation. You may be placed into question queue at any time by pressing star one on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Harold Tamayo, Vice President, Finance and Investor Relations. Harold, you may now begin. Thank you, Kevin, and good morning, everyone. Joining me on today's call is Karen Zaderej, Axogen's Chairman, Chief Executive Officer, and President, and Nir Naor, Chief Financial Officer. Karen will discuss the quarter and full year 2023, and Nir will provide an analysis of our financial performance, guidance, and discuss our outlook for the year, followed by a question-and-answer session. Today's call is being broadcast live via webcast, which is available on the Investors section of the Axogen website. Following the end of the live call, a replay will be available in Investors section of the company's website at www.axogeninc.com. Before we get started, I'd like to remind you that during this conference call, the company will make projections and forward-looking statements, including our expectations regarding our ability to expand our footprint, expand core accounts, anticipate growth for revenue categories, penetration of core accounts, marketing opportunities with nerve applications associated with emergent trauma, breast, OMF, and surgical treatment of pain and new products. Our expectations regarding the timing of a launch for Avive+, our statement regarding the timing of the complete Biologics License Application submission for Avance Nerve Graft, as well as statements of the timing of the approved BLA. Our expectations that, assuming approved the BLA, Avance Nerve Graft will be designated as a reference product and expected market exclusivity of such designation. Our belief that our balance sheet will continue to be sufficient to bridge through to cash flow breakeven and longer-term profitability. Our expectation is that we will continue trending towards cash flow breakeven, and our belief that trends towards operating leverage will allow us to maintain a strong balance sheet position and provide ample support as we work towards profitability. Forward-looking statements are based on current beliefs and assumptions and are not guarantees of future performance and are subject to risks and uncertainties, including, not without limitation, the risks and uncertainties reflected in the company's annual and periodic reports, such as hospital staffing issues, regulatory processes and approvals, surgeon and product adoption, and market awareness of our products. The forward-looking statements are representative only as of the date they are made and except as required by applicable law. We assume no responsibility to publicly update or revise any forward-looking statements. In addition, for a reconciliation of non-GAAP measures, please reference today's press release and our corporate presentation on the Investor section of the company's website. Now, I would like to turn the call over to Karen. Karen? Thank you, Harold, and thank you all for joining us today as we discuss our 2023 fourth quarter and full year financial results. 2023 was a solid year of key accomplishments, and we enter 2024 with a strong commercialization strategy, fueled by innovation and focused execution by our sales team. Full year 2023 revenue was $159 million, a 14.7% increase compared to 2022. In the back half of 2023, we saw improved commercial execution, during this period, we estimate that revenue from our emergent trauma procedures grew in the mid-single digits, and revenue from scheduled procedures grew above 25% as compared to the same period in 2022. As a reminder, these estimates of procedure categories are based on available data received from hospitals and sales reps and assumptions regarding specific surgeon practices and account information, and as such, are subject to the limitations of the data received and/or assumptions. We're pleased with our progress and execution as we drive long-term growth, leveraging innovation, clinical data, surgeon education, and patient activation. We're appreciative of our ongoing surgeon engagement and feedback as they continue to integrate Axoguard HA+ into their nerve protection algorithm, finding differentiated applications as compared to Axoguard Classic. We're confident that Axoguard HA+ will expand the adoption of nerve protection products and will help more patients with nerve injuries. Additionally, we're continuing to expand our offering for nerve protection with Avive+ Soft Tissue Matrix, which we anticipate will be commercially available in the second quarter of 2024. Avive+ is a resorbable nerve protection product that functions as a barrier, providing temporary protection and tissue separation during the critical phase of healing for nerve injuries. We believe Avive+ will be regulated as a Section 361 tissue product and will further strengthen our position in nerve protection, supporting emergent trauma and the surgical treatment of pain. In 2023, we also launched our ReSensation breast neurotization technique for women who choose an implant-based reconstruction. We believe this innovative technique could apply to an additional 10%-15% of all breast reconstruction patients. We're pleased with the surgeon engagement, positive feedback from our educational programs, and the early adoption of this new technique. This approach will allow more patients to have the opportunity for sensory restoration following their mastectomy and reconstruction. In August, the RECON study was published in the Journal of Hand Surgery. The publication includes the author's analysis of the results, which found that Avance returned a greater degree of functional recovery than conduits, and superiority was demonstrated as gap length increased. We believe that this addition of level one evidence supporting the efficacy of Avance Nerve Graft in published literature continues to play an important role in surgeon clinical decision-making, especially with middle adopter surgeons. This study adds to a strong pool of clinical evidence supporting Avance Nerve Graft. In combination with the recent publications of the meta-analysis, the premier all-payers cost comparison study, and the US cost-effectiveness analysis, these four studies provide a package of compelling evidence for both clinicians and payers. During the year, we completed the validation and transitioned into our new processing facility near Dayton, Ohio. This facility was designed for long-term growth and expansion, providing three times our previous capacity. This new facility will also support our BLA for Avance Nerve Graft. Now turning to our fourth quarter results. We're pleased with our performance during the quarter. Revenue from the quarter increased by 18.7% to $42.9 million compared to last year. We estimate that revenue from the emergent trauma represented approximately half of total revenue and grew mid-single digits compared to last year. As a reminder, emergent trauma generally results from injuries that initially present in an ER. These procedures are typically referred to and completed by a specialist, either immediately or within a few days following the initial injury. We believe scheduled procedures also represented approximately half of total revenue. During the quarter, we estimate that this category grew more than 25% versus the prior year. As a reminder, scheduled procedures are generally characterized as procedures where a patient is seeking relief of a nerve condition caused by a nerve defect or surgical procedure. These include breast reconstruction following a mastectomy, nerve reconstruction following the surgical removal of a painful neuroma, nerve decompression, and oral and maxillofacial procedures, such as a mandible reconstruction. Strength in this category reflects the opportunity to provide improved quality of life outcomes for patients, compelling clinical data, effective surgeon education, and implementation of patient activation programs. As mentioned in today's press release, our growth strategy continues to be focused on going deeper into core accounts, where we see significant opportunity to expand our footprint. As a reminder, core accounts are defined as those generating more than $100,000 in revenue over the trailing twelve months. Revenues from core accounts represent approximately 65% of total revenue. Growth was primarily driven by increased productivity of our direct sales force as they gained deeper surgeon adoption and expanded use cases of our products within these core accounts. We ended the fourth quarter with 116 direct sales representatives, up one from a year ago and flat sequentially. We will continue to evaluate and add sales reps as their territories approach targeted levels. Our direct sales force is supplemented by independent sales agencies that represented approximately 10% of our total revenue. In Q4, growth was broad-based across all applications and products. We were pleased by the contributions from innovations in new products and new applications. We continue to raise awareness. We also saw strong surgeon and patient interest in neurotization and implant-based breast reconstruction, and expanded the number of surgical teams trained in this important new application. Moving on to updates in our growing body of clinical evidence. Over the years, we've made significant investments to develop quality clinical evidence to demonstrate the safety, performance, economics, and utility of our nerve repair solutions. Our active clinical programs are progressing as expected. At the end of the quarter, we have 245 peer-reviewed publications, including trauma, breast. This January, we announced positive top-line results from the REPOSE study and protection of the terminated nerve end with Axoguard Nerve Cap. This post-marketing study met its primary and other subjects as compared to clinical decision-making. Now turning to the BLA for Avance Nerve Graft. We're encouraged by the positive interactions and have aligned with the FDA on a rolling submission process and the content of the modules for submission. We now anticipate the filing to be completed in Q3 of 2024, with potential approval in mid-2025. As a reminder, a BLA approval will complete the regulatory transition of Avance Nerve Graft from a 361 tissue product to a 351 biological product. Importantly, we believe Avance will be designated as the reference product for potential biosimilars, providing 12 years of market exclusivity. With over 100... Our mission of revolutionizing the science of nerve repair. Now I'll turn the call over to Nir to provide a review of our financial highlights and guidance. Nir? Thank you, Karen. Since ramping up and meeting people on the team, I'm very excited about the Axogen story and the potential of the company. Moving to the financial results. For this quarter, our revenue reached $42.9 million, marking 18.7% growth from the fourth quarter of 2022. This growth is attributed to a 10.5% increase in unit volume from emergent trauma, represented approximately half of total revenue. We estimate that revenue from scheduled proceed-- Our gross profit for the quarter was $33.8 million, an increase from the $30 million recorded in the fourth quarter of 2022. This represents gross margin of 78.7%, down from 83% in the same period last year. This change is mainly driven by the costs associated with starting tissue processing at our new facility. Our total operating expenses for the quarter increased by 3.7% to $37 million, up from $35.6 million in Q4 of 2022. Specifically, our sales and marketing expenses for the fourth, we saw improved sales force productivity. Research, $7.3 million from $6.8 million in 2022, driven by costs related to the BLA. As a percentage of total revenues, total R&D expenses reduced to 17%, down from 18.8% in the last quarter of the previous year. Percent to $7.5 million in Q4 of 2023, from $8.9 million in Q4 of 2022, driven mainly by stock forfeitures due to the departure of executives from our company. The quarter ended with a net loss of $3.9 million, or $0.09 per share, compared to a net loss of $5.4 million, or $0.13 per share in the fourth quarter of 2022. However, we recorded an adjusted net loss of $2.6 million-$0.6 million compared to an adjusted EBITDA loss of zero point- Our guidance. As outlined in today's press release, we're issuing our full year guidance for 2024. We expect revenue to be in the range of $177 million to $100- the range of 76%-79%. In the future, we expect our gross margin to benefit from improved capacity over price increases. In summary, we're pleased with our fourth quarter performance. We will continue to execute our strategies, invest in innovation, improve our productivity, and- If you'd like to be placed into question queue, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. Once again, that's star one to be placed into question queue. One moment please, while we pull for questions. Our first question today is coming from Chris Pasquale from Nephron Research. Your line is now live. Thanks. Karen, Avive was annualizing at close to $8 million in sales before- That we launched that was Avive+, that we withdrew because of changes in regulatory classifications from the FDA, and we've launched Avive+ to help move back into that segment of a temporary protection barrier, which we think is an important tool for surgeons. I don't think it's gonna be an immediate ramp-up, I don't want to overplay that as, something that's gonna completely pop into this, you know, next few quarters. We do have some surgeons who are very anxious to get this product because they used it that we have and allow us to continue to see growth overall in protection. I t won't ramp immediately up into that into that size of of revenue. There is some cannibalization. Surgeons had to turn to another tool when they no longer had Avive to try and still provide some protection for their nerves. But we do.. .. During 2024. The guidance is a little bit lower than what we were thinking. I'm assuming that's related to the new facility. Can you give, do you see a pathway back to, you know, the 82%-83% margins the company, you know, enjoyed a year ago? Yeah, thank you for the question. Y eah. So indeed, as we mentioned, we fully transitioned to the new processing facility end of last year. It is an important milestone for our BLA. It is designed for long-term growth and basically has capacity, which is three times our previous one, which is very good for our long-term expansion and the margin. That said, in the short term, it's running at a fraction of its total capacity, and this is one of the drivers for the lower margin. W e're ramping it up, learning about the various efficiencies. That said, we want to give guidance that we feel fully confident with. We expect the more.. ..sequential decreases in gross margin through the year, not a, not a first half dip and then a second half rebound? Right. I mean, we're basically selling old inventory, which was produced in the prior and the previous facility. T his is our... But again, we're learning all of those impacts, as I said, of the new facility. For the total year, our guidance is, as we said, $76-$79, with definitely a clear expectation for improvement in the long. Then, you know, in terms of scenarios and healthcare utilization environment at the low and high ends of the range? Yeah, W e measured growth through the year, driven predominantly by productivity improvements with our existing sales team. Think of it as about the same number of reps, maybe up or down a few, but in the same size, not a big expansion of sales teams. It's driven by productivity and a real focus in driving that growth in our core accounts. T hat's our strategy. That's how we think we're continuing to build this out. W e've drawn that out and have taken- Provide any color on how you're thinking of the growth differential in 2024 between emergent trauma and scheduled non-trauma? Can you break that out for us or, or help us think about that? Well, as we've talked about before, we think the conversion process in trauma, while it's a very large market, is just hampered by the very nature of the fact that it's an unscheduled procedure, and surgeons don't take trauma call every day in a given month. W e think that the trauma growth will continue to be paced through continued growth, but having you know, having to reach those surgeons in a longer timeframe with a greater number of adoption steps. In scheduled procedures, by the very nature of the fact that they're scheduled, you can plan to be with the surgeon as they adopt a new technology, work with them in those cases, and help change their practice patterns over a more discrete amount of time. We think the adoption process in scheduled cases can be, you know, more rapid than what you see in trauma. I t's a blend of those two that is what made up our overall guidance. Okay, thanks, Karen. M aybe if I could just squeeze one last one in. Can you maybe just elaborate on how you're thinking about seasonality and sales cadence through the year? Yeah, great question. A s we've talked about in the past, trauma is has a peak during the time periods where people are more active. A s our business was originally trauma, you saw a second quarter, there was a big jump up. Second quarter to the third quarter, there was a follow that cadence. Y ou're seeing some shifts in our cases will be driven, like most other elective scheduled procedures, they tend to be heavy towards the end of the year. A little slight nuance difference for breast reconstruction, where many women prefer not to have their breast reconstruction during that holiday period. In most scheduled elective procedures, you'll see a push towards the end of the year, and it will be a little bit lighter at the beginning of the year, and then more of a steady slope through the, throughout the year. A gain, we're going to see some shifts over time in the cadence quarter to quarter as we balance between trauma and scheduled cases. Okay, thanks, Karen. Thank you. Next question today is coming from Mike Kratky from Leerink Partners. Your line is now live. Hi, everyone. Thanks for taking the line. W hat's the latest you've been hearing from KOLs and physicians on the extent to which having that entire utilization, what are the key factors that are driving that? Well, we're really excited about continuing to move forward and, getting to the final stage of, our submission on the BLA. It's been a long process for us, and we had a very productive meeting with the FDA that, we think laid out a clear path for us as we go forward. Y eah, we are turning our sights not just to the submission, but to our commercialization post BLA. Look, from a surgeon standpoint, the surgeons really care more about the data and that RECON publication than they care about the regulatory classification of, of a particular product. W e do think it will be helpful to continue to drive standardization, especially with middle adopters and account them. We also think that having the BLA, and again, the data, will be helpful as we continue to work with payers to make sure that Avance is listed as non-experimental on their payers' algorithms. W e think that it'll be continued to be helpful as we continue to grow, but the first step actually was getting this recent publication of the RECON data, which we're wanting to make sure that surgeons see so they can make an informed choice in their clinical decision making. Got it. Yeah, that makes sense. T hen maybe just one separate one. You know, you saw great growth in the scheduled procedures in Q4 2022. Would be curious if you could provide some additional color on which procedures within that category were driving some of that growth, and whether you've seen some of that momentum continue so far in early 2024. Well, all I mentioned in the script, all of our application areas grew, so and with all of our products. I t wasn't one hit. It's really for us to continue to develop and grow at this market and expansion in as we've entered here into Q1. Understood. Thanks very much. Thank you. Next question is coming from Caitlin Cronin from Canaccord Genuity. Your line is now live. Hi, thanks for taking the questions, and congrats on a great quarter. Thanks, Caitlin. Yeah. Hi, everyone. Just to start with 2024 guidance, it seems to imply a deceleration year-over-year at the midpoint, even though it seems like scheduled procedure growth has seemed to tick up. Any, any kind of reason for that? w here do you think the mix between scheduled and emergent trauma could trend really over time? Well, again, I think we're taking a measured approach. We looked at this not just on the, we had great momentum coming out of the year, but really looking at the total year to take a measured approach and think about our overall guidance. T hat was the thinking behind it. Again, so far, we've been pleased how we saw the beginning of the year, but we're wanting not to get out over our skis on this. Okay, makes sense. Where did active accounts end the year? Can somebody pull up the active account number for me? W e generally are focusing, and it will be in the deck that we'll get out, but we're generally focusing on the core accounts, 'cause that's where the majority of our revenue comes from, it's from those core accounts. O f course, active accounts grow into core accounts. I t's important to make sure that we have that, that feeder pool of active accounts, but our real focus is on thinking about how can we take these accounts to be $100,000 or bigger, so that, so that we can continue to go deeper and become a standard of care in those core accounts. If you remember, an active account is a pretty low threshold. It means that we had only six orders in the past, and you've got a surgeon who has started to use the product in some small way. 1,006 active- and build a bigger base. Understood. Thank you so much. Thank you. Next question today is coming from David Turkaly from Citizens JMP. Your line is now live. Hey, good morning. Good morning. I was wondering if you might provide us a little additional detail of when you look at the 360 product, or how many of them. Are there accounts that are doing, you know, the trauma procedures as well as the schedules? h ow kind of popular or how common is that? Yeah, it's going to be hard to answer that, because it's some of all of those things. Look, most of our core accounts use more than one product. M ost are not fully penetrated, that they use all of our products in all of the applications and algorithms. I nitially, in sort of short digital nerve injuries and work their way up to complex, mixed in motor injuries, across a stairstep process of adoption. M ost of our accounts are at an early stage of penetration. That's why we think we want to continue to focus on that core account to become a standard of care in those core accounts. There are some core accounts that are trauma only. There are some core accounts that are scheduled procedures only. It is still generally what it takes to become a core account is one surgeon who will then be about $100,000 in revenue, and the rep's job is to continue to expand out to other surgeons across all of the applications. B ecause the threshold is only $100,000, like I said, there can be a core account, there can be one surgeon who takes a trauma call, and that could be a core account, but we got a lot of opportunity to build it from there. Thank you for that. Then maybe one for Nir. Congrats on the, you know, the progress on the bottom line. I guess, as we're looking into next year, thinking in that direction, I was wondering if you'd make any comment on sort of, you know, what you think that EBITDA loss might look like or, you know, maybe compared to what 2023 was directionally... Any help there would be great. Yeah, I mean, we don't specific figures, I would say, you know, a couple of things that I would be looking at, revenue growth and benefit of the operational leverage and the economies of scale. I think this is the most important thing. In addition to that, better and continued focus on resource allocation, sales force productivity. In addition to that, a couple of tailwinds, one of them impacting the EBITDA and the other one, the cash balance. But the royalties on events that we have been paying for the past couple of years, around a bit over $3 million in 2023, they rolled off at the end of 2023.T hose are sort of the high-level levers that I would be looking at when you're looking at the improvement from last year to this year when it comes to bottom line. Thank you. Thank you. As a reminder, that's star one to be placed into question queue. Our next question is coming from Ross Osborn from Cantor Fitzgerald. Your line is now live. Hey, guys, good morning. Thanks for taking our question. Good morning. In your prepared remarks, you mentioned seeing AxoGuard HA+ being used in new types of cases versus classic offering. Could you maybe just walk us through some of those use cases? Sure. One of the things we're really excited about Axoguard HA+ is the HA layers provide a slippery, gliding surface. W hen you think about your extremities and where you need to bend or move, that slippery layer helps when a nerve is going around a large joint. E lbows, knees, hips, those are all areas where that gliding surface can be important to make sure that the nerve remains free from attachments and can move smoothly across and through that joint. T hat's one of the big areas that we see surgeons really seeing a great application for the Axoguard HA+. W e continue to see being interested in how they're using it, seeing some great applications in those areas where they wanna have that gliding surface and getting some very positive feedback about the product. Okay, great. T hen maybe lastly, for us, just on OpEx. So sounds like hiring may be minimal this year in terms of sales reps. W ould you walk us through any new or expanded marketing initiatives? And also remind us, what's at stake on the R&D line, please? Thank you. Yeah, we think of it as, from a sales rep number, that we will stay very close to that 116 number, maybe up or down a few reps from that. I t will stay very close to the 116 number. In terms of new things, again, we've already talked about the Avive+, which will be coming up here shortly, so we'll have a new product continuing to focus in different parts of nerve protection. We aren't looking at any big launch in a new application, but we are doing continued development work in several application areas and are injured in many types of procedures. We have a medical affairs team that really focuses on advanced techniques in nerve repair and looking at new expansion areas. A t this point, I don't have anything that I wanna tell you is a confirmed expansion area, but to say that our R&D team continues to work on it and sees some promising new areas for us to look into. Great. Thank you. Thank you. We've reached the end of our question-and-answer session. I'd like to turn the floor back over to Karen for any further closing comments. Well, thank you. As we conclude today's earnings call, I wanna express my appreciation to our team for their exceptional efforts and to all the participants for your attention and contributions. The dedication of our staff has been pivotal in achieving the milestones we discussed today, and we look forward to sharing our continued progress with you in the future. Thank you. That does conclude today's teleconference webcast. You may disconnect your line at this time and have a wonderful day. We thank you for your participation today.